Zealand Pharma AS (OCSE:ZEAL)
kr 827 -18 (-2.13%) Market Cap: 58.67 Bil Enterprise Value: 50.13 Bil PE Ratio: 0 PB Ratio: 6.38 GF Score: 61/100

Zealand Pharma A/S at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 01:40PM GMT
Release Date Price: kr195.4 (-0.20%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Okay. Good morning, everyone, and welcome to the 9:40 session on day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover European and U.S. biopharma names here at the firm. It's my great pleasure to be hosting Zealand Pharma in a fireside chat discussion today. And with us is Emmanuel Dulac, who is CEO of the company; and Matt Dallas, CFO of the company as well. And so with that, Emmanuel and Matt, welcome.

Matthew Donald Dallas;S;Senior VP;CFO
Zealand Pharma A

/-&

Thanks, Graig.

Emmanuel Dulac;S;CEO;President
Zealand Pharma A

/-&

Thank you, Graig.

Questions & Answers

Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot